BridgeBio Soars After Drug Gets Nod in Rare Heart Condition

Bloomberg11-25

(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486303684?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pRk.MSIVzRKR3zMPDldCGg--~B/aD0zOTUxO3c9NTkyNzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_markets_842/306b0a3efa17279181795656cf7c2a5c","is_english":true,"pubTime":"2024-11-25 22:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486303684","market":"us","top_or_hot":-1,"title":"BridgeBio Soars After Drug Gets Nod in Rare Heart Condition","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bridgebio-soars-drug-gets-nod-144022155.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Soars After Drug Gets Nod in Rare Heart Condition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Soars After Drug Gets Nod in Rare Heart Condition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bridgebio-soars-drug-gets-nod-144022155.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bridgebio-soars-drug-gets-nod-144022155.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999011175.SGD","symbol_name":"Nikko AM Global Dividend Equity Dis SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/bridgebio-soars-drug-gets-nod-144022155.html","article_id":"2486303684","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pRk.MSIVzRKR3zMPDldCGg--~B/aD0zOTUxO3c9NTkyNzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_markets_842/306b0a3efa17279181795656cf7c2a5c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486303684","pubTimestamp":1732545622,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":" -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.The therapy, to be sold under the name Attruby, gained Food and Drug Administration clearance on Friday to treat patients with transthyretin amyloid cardiomyopathy, or ATTR-CM. The list price will be $18,759 for a 28-day supply.BridgeBio shares rose as much as 28% at the start of trading Monday in New York, their biggest intraday gain since July, 2023. They had lost 42% this year through Friday’s close.The approval pits the small biotech’s drug against Pfizer’s Vyndaqel and Vyndamax, two drugs that use the same active ingredient, tafamidis, to treat the condition. Pfizer’s drugs are priced at the equivalent of about $20,600 for a 28-day supply and generated $3.3 billion in sales last year.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","PFE":"辉瑞","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4581":"高盛持仓","BBIO":"BridgeBio Pharma, Inc.","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4592":"伊斯兰概念","BK4599":"减肥药","BK4585":"ETF&股票定投概念","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4534":"瑞士信贷持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"BridgeBio在治疗罕见心脏病的药物获得批准后股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9,"PFE":0.9},"content_text":"(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.\nThe therapy, to be sold under the name Attruby, gained Food and Drug Administration clearance on Friday to treat patients with transthyretin amyloid cardiomyopathy, or ATTR-CM. The list price will be $18,759 for a 28-day supply. \nBridgeBio shares rose as much as 28% at the start of trading Monday in New York, their biggest intraday gain since July, 2023. They had lost 42% this year through Friday’s close. \nThe approval pits the small biotech’s drug against Pfizer’s Vyndaqel and Vyndamax, two drugs that use the same active ingredient, tafamidis, to treat the condition. Pfizer’s drugs are priced at the equivalent of about $20,600 for a 28-day supply and generated $3.3 billion in sales last year.\nAttruby’s label says it achieves near-complete stabilization of transthyretin, a transport protein that becomes misshapen and loses functionality in ATTR-CM. That may help “convince clinicians that it is best-in-class and differentiated from tafamadis,” according to Danielle Brill, an analyst with Raymond James. \nOnce thought to be rare, ATTR-CM is being diagnosed more frequently due to advances in testing, making it an attractive market for drugmakers. More than 300,000 patients globally have the condition. \nBridgeBio had won approval previously for two drugs to treat less-common diseases. ATTR-CM will be the company’s biggest market by far, and investors are waiting to see if the relatively small biotech can compete with Pfizer’s larger sales force.\nAbout 5,000 to 7,000 new cases of the condition are identified in the US annually, researchers estimate. To succeed, BridgeBio will need many doctors to prescribe its drug — a twice-daily pill — ahead of Pfizer’s.\nEven more competition is on the horizon. Alnylam Pharmaceuticals Inc. is expected to get approval next year for its drug to treat ATTR-CM. Earlier this month, Intellia Therapeutics published positive results from an early trial of its gene-editing treatment for the condition. Ionis Pharmaceuticals Inc. is also developing a drug for the disease.\n(Updates with shares, analyst’s comment starting in third paragraph.)\n©2024 Bloomberg L.P.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486303684"}